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In the postero-lateral hypothalamus are located two neuronal systems that utilize the neuropeptides
melanin-concentrating hormone (MCH) and hypocretins (also called orexins) as neuromodulators. These
systems have reciprocal connections between them, and project throughout the central nervous system.
MCH has been involved in the generation of sleep, mainly REM sleep, while hypocretins have a critical
role in the generation of wakefulness.
MCHergic activity is also involved in the pathophysiology of major depressive disorder (MD). In this
regards, intracerebral administration of MCH promotes pro-depressive behaviors (i.e., immobility in the
forced swimming test) and REM sleep hypersomnia, which is an important trait of depression. Fur-
thermore, the antagonism of the MCHR-1 receptor has a reliable antidepressant effect, suggesting that
MCH is a pro-depressive factor. Hypocretins have been also involved in mood regulation; however, their
role in depression is still on debate.
Taking these data into account, we explored whether systemic subchronical treatment with Fluox-
etine (FLX), a serotonergic antidepressant, modifies the concentration of MCH in the cerebrospinal fluid
(CSF), as well as the preproMCH mRNA expression. We also evaluated the hypocretinergic system by
quantifying the hypocretin-levels in the CSF and the preprohypocretin mRNA expression.
Compared to control, FLX increased the levels of preprohypocretin mRNA without affecting the hy-
pocretin-1 CSF levels. On the contrary, FLX significantly decreased the MCH CSF concentration without
affecting the preproMCH gene expression. This result is in agreement with the fact that MCH serum level
diminishes during the antidepressant treatment in MD, and supports the hypothesis that an increase in
the MCHergic activity could have pro-depressive consequences.
& 2016 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major depressive disorder (MD) is a serious, recurrent, het-
erogeneous, and disabling psychiatric illness, that will affect one
out of five people in their life-time and is the leading cause of
disability worldwide; however, the current knowledge about the
mechanisms associated with the pathogenesis of this disease is
still limited, and current treatments remain ineffective in a large
subset of patients [2,15,22].
In accordance with the monoamine theory of MD, the main
classes of antidepressants are directed to elevate the synapticduction and Hosting by Elsevier B.
o).
iation of Sleep.levels of monoamines in the brain. However, these drugs are as-
sociated with several limitations, which include limited clinical
efficacy, therapeutic lag with high risk of suicide and morbidity
during latent period and treatment resistant cases [32,36].
Therefore, in order to improve the understanding of MD and its
treatment, the study of the contribution of other neuromodulatory
systems in this pathology is warranted.
The hypothalamus is considered the highest hierarchical
structure in the control of homeostasis, and the postero-lateral
region has been considered an integrative area involved in med-
iating different behaviors and processes that are critical to this
function. Within this and adjacent regions of the hypothalamus,
there are neurons that utilize the neuropeptides melanin-con-
centrating hormone (MCH) or hypocretin-1 and 2 (also called or-
exin A and B, respectively) as neuromodulators [4,27]. Both groups
of neurons project throughout the central nervous system [4,27].V. This is an open access article under the CC BY-NC-ND license
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action, MCH has the opposite effect, and whereas the MCHergic
system tends to conserve energy, the hypocretinergic system is
considered to have catabolic survival functions [7,28]. Moreover,
whereas the hypocretinergic neurons are involved in the genera-
tion and maintenance of wakefulness and degeneration of these
neurons produces narcolepsy, a sleep pathology, the MCHergic
system promotes sleep, mainly rapid eyes movement (REM) sleep
[33,34].
The hypocretinergic system has been involved in mood reg-
ulation and reward; however, the precise role of hypocretins in
behavioral and neurophysiological impairments observed in de-
pression is still unclear. The fact that both hypoactivity and hy-
peractivity of the hypocretinergic system have been found to be
associated with depression (see [24] for a comprehensive review),
may reflect the heterogeneous nature of MD.
Borowsky et al. [5] have demonstrated in rats that the MCH-R1
antagonist SNAP-7941 has an antidepressant-like profile in the
forced-swim test (FST, a widely used experimental paradigm for
screening antidepressant activity), suggesting that MCH is a pro-
depressive neuromodulator. This finding was confirmed by pre-
clinical studies [6,8,11,12,19,35,38], but the mechanism by which
the MCHergic system participates in mood regulation is still un-
known. However, recent studies showed that MCH suppresses the
activity of presumed serotonergic neurons of the dorsal raphe
nucleus (DRN) [9], and decreases the release of serotonin within
this nucleus [37]; by this means, MCH might promote a depressive
mood [19].
Recently, Schmidt et al. [30] showed that MCH serum level
decreases in patients with MD during antidepressant treatment. In
the present study, with the hypothesis that antidepressant phar-
macological treatment decreases MCHergic activity, we analyzed
the MCH concentration in the cerebro-spinal fluid (CSF) as well as
the hypothalamic expression of the preproMCH (Pmch) gene in
rats, following subchronical treatment with Fluoxetine (FLX), an
antidepressant drug of the selective serotonin reuptake inhibitor
(SSRI) group [40]. In order to know if FLX also modulates the hy-
pocretinergic system, hypocretin-1 levels in the CSF and pre-
prohypocretin (Hcrt) gene expression were also analyzed.2. Methods
Twenty Wistar adult male rats (280–300 g) were used in this
study. The animals were maintained with food and water ad libi-
tum, and kept under controlled conditions (temperature 2272 °C;
12:12-h light-dark cycle). All of the experimental procedures were
conducted in accordance with the Guide for the Care and Use of
Laboratory Animals (8th edition, National Academy Press, Wa-
shington DC, 2010) and approved by the Institutional Animal Care
Commission. Adequate measures were taken to minimize pain,
discomfort and stress of the animals. All efforts were made in
order to use the minimal number of animals necessary to produce
reliable scientific data.
2.1. Experimental procedure
Fluoxetine hydrochloride was kindly donated by Gador La-
boratories (Montevideo-Uruguay) in powder form. Animals
(n¼10) were treated with three doses of FLX (each of 20 mg/kg, i.
p.) 23 h, 5 h and 1 h before CSF extraction and euthanasia. This
treatment was chosen because it reversed the pro-depressive ef-
fect of MCH [19]. Control group (n¼10) received vehicle (saline)
injections under the same schedule.
As in a previous study, CSF taps from the cisterna magna were
performed under ketamine (90 mg/kg) and xylazine (5 mg/kg)anesthesia using a 1-ml syringe connected to a 27.5-G needle [10].
The taps were carried out during the light phase (8 h after the light
was on). CSF limpid aliquots (100–150 mL) were frozen im-
mediately over dry ice and stored at 80 °C until used. Thereafter,
euthanasia was performed by decapitation. CSF samples with
blood were discarded.
2.2. CSF analysis
CSF levels of MCH and hypocretin-1 were measured by means
of fluorescent immunoassay kits (Phoenix Pharmaceuticals, CA,
USA) [10]. These fluorescence immunoassay kits were designed to
detect very specifically MCH or hypocretin-1 in a range of 0–
10.000 pg/ml based on the principle of “competitive” enzyme im-
munoassay. The concentrations of the samples were within the
linear range of the standard curve provided by each kit; the results
we obtained displayed high accuracy and reproducibility.
Both hypocretin-1 and MCH were quantified in the same CSF
sample. In order to determine the concentration of one of these
neuropeptides, 50 mL of CSF were assayed in duplicates; the mean
of both measures was considered the concentration of the peptide
for the corresponding animal. The samples were incubated in an
immunoplate with 25 mL of rabbit anti-MCH or anti-hypocretin-1
antibodies at 4 °C for 20 h. Next, 25 mL of the corresponding bio-
tinylated peptide was introduced and the samples were incubated
at room temperature for 1.5 h. The immunoplates were washed
four times with 200 mL of assay buffer. Subsequently, 100 mL of
streptavidin-horseradish peroxidase was applied, and the samples
were incubated at room temperature for 1 h. After incubation, the
immunoplates were washed four times with 200 mL of assay buf-
fer. Next, 100 mL of substrate solution was applied and the samples
were incubated at room temperature for 20 min. The reaction was
terminated by adding 100 mL of stop solution. The fluorescence
product was detected (excitation 325 nm; emission 420 nm) using
a SpectraMax M2 fluorometer (Molecular Devices, Sunnyvale, CA,
USA). The fluorescence readings were corrected using blanks, and
the results were compared to their respective standard curves.
2.3. Gene expression analyses
Gene expression was analyzed as in a previous study of our
group [10]. After euthanasia, the brains were immediately re-
moved and the hypothalamus were harvested, frozen immediately
over dry ice, and stored in microtubes at 80 °C until used. RNA
was extracted using Brazol reagent (LGC Biotecnologia). The
quantity and quality of the RNA extracted was measured using the
Nanodrop 8000 spectrophotometer (Thermo Scientific). Total RNA
(1 mg) was used to synthesize the complementary DNA (cDNA)
using ImProm-II Reverse Transcriptase (Promega).
Diluted cDNA sample was used as template for real-time PCR
amplification using 2X Maxima SYBR GREEN/ROX qPCR Master
Mix (Thermo Scientific) and the respective primers for Pmch (NCBI
Gen Bank accession number: Pmch mRNA, NM_012625.1) and Hcrt
(NCBI Gen Bank accession number: Hcrt mRNA, NM_013179.2).
Amplification and detection were performed using an Applied
Biosystems 7500 Real-Time PCR system. A two-step cycling pro-
tocol was used.
Target mRNA levels were normalized for each well to en-
dogenous control; beta actin (NCBI Gen Bank accession number:
beta actin mRNA, NM_031144) and alpha tubulin 1a (NCBI Gen
Bank accession number: Tuba 1 mRNA, NM_022298.1) were used
to confirm the results. PCR products were subjected to a heat
dissociation protocol (gradual increase of temperature from 60 to
95 °C) for melting curve analyses.
The relative gene expression was calculated using the com-
parative Ct (2 -deltadelta Ct) method [20].
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The data are reported as the means7S.D. All the parameters
were tested concerning normality (Kolmogorov-Smirnov's test)
and homogeneity (Levene's Test). While CSF data showed a para-
metric distribution, gene expression data were non-parametric;
so, these data were normalized using the Z-score to allow the
utilization of parametric tests. The significance of the mean be-
tween the peptides concentrations, the MCH/hypocretin-1 CSF
ratio (that was calculated for each CSF sample) or mRNA levels
following vehicle and FLX treatments, was analyzed by the two-
tailed unpaired Student t test. The level of significance was set at
po0.05.Fig. 2. Bar chart that shows the Pmch (A) and Hcrt (B) gene expression following
vehicle (control, CT) or fluoxetine (FLX) treatments. Results are presented as mean
7S.D. *, p¼0.02, two-tailed, unpaired Student’s t test.3. Results
In control condition (vehicle treatment) the concentration of
MCH in the CSF was 146.6760.5 pg/ml, while the concentration of
hypocretin-1 was 218.5753.8 pg/ml. As it is shown in Fig. 1(A),
FLX treatment decreased the CSF level of MCH (69.8731.4 pg/ml,
47.6% of the control, p¼0.004, t¼3.34). FLX did not modify the
hypocretin-1 concentration (206.5751.7 pg/ml, p¼0.63, t¼0.48)
(Fig. 1B). We also analyzed for each CSF sample the MCH/hypo-
cretin-1 ratio. FLX tended to decrease the MCH/hypocretin-1 ratio
(0.7370.48 in control group Vs. 0.3670.20 in FLX group,
p¼0.057, t¼2.07).
The expression of Pmch gene in the hypothalamus did not
changed with FLX treatment (p¼0.55, t¼0.61) (Fig. 2A). In
contrast, FLX treatment increased the level of the Hcrt mRNA
(p¼0.02, t¼2.49; Fig. 2B).4. Discussion
In the present study, we found that MCH concentrations in the
CSF of normal rats decrease following subchronical treatment withFig. 1. Bar chart that shows the MCH (A) and hypocretin-1 (B) CSF concentration
following vehicle (control, CT) or fluoxetine (FLX) treatments. Results are presented
as mean 7 S. D. *, p ¼0.004, two-tailed, unpaired Student’s t test.FLX. This result is in agreement with the decrease in MCH serum
level following 4 weeks of antidepressant treatment in depressive
patients [30]. The diminution of MCH within the CSF could be
mediated by a reduction in the activity of the MCHergic neurons.
In fact, FLX increases serotonin synaptic levels [40], and serotonin
hyperpolarizes MCHergic neurons [39]. In contrast, the expression
of Pmch was not modified. These results suggest that FLX could be
mediating a reduction in the release of the peptide rather than a
decrease in its synthesis; however, measurements of the hy-
pothalamic pre-proMCH protein are needed to confirm this
hypothesis.
In agreement with these results, preclinical studies have in-
volved MCH with depression; for example, local administration of
MCH into the DRN induced a depressive-like behavior evaluated in
the FST [19,38]. This effect was prevented by systemic and sub-
chronic treatment with either FLX and nortriptline (a nora-
drenergic antidepressant) [19,38]. Furthermore, MCH im-
munoneutralization (i.e. anti-MCH antibodies microinjected into
the DRN) elicited an antidepressant behavioral response in the FST
[19]. Microinjections of MCH into the DRN not only produce a
depressive-like effect that is prevented by antidepressant, but also
produce a REM sleep hypersomnia [17,18,38], that is a classical
trait of MD [1,3,26]. Georgescu et al. (2005) also showed an in-
crease in the immobility time in the FST induced by bilateral mi-
croinjection of MCH into the nucleus accumbens [13], demon-
strating that other brain areas are also involved in depressive-like
behaviors induced by MCH.
Katai et al. (2013) have recently explored the effect of acute
antidepressant treatment (escitalopram, also a SSRI) on c-fos ex-
pression in MCHergic neurons during REM sleep rebound [14].
They demonstrated that escitalopram decrease the number of
active (Fos positive) MCHergic neurons, which is in agreement
with the reduction of MCH concentration in the CSF observed in
the present study, and in accordance with the hypothesis that the
MCHergic system might be involved in the pathophysiology of
depression.
Although there is growing evidence that involve the
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role is still controversial [24]. A recent study reported that there is
a decrease in depressive-like behavior in hypocretin receptor-1
knockout mice, whereas hypocretin receptor-2 knockout mice
exhibit an increase in the depressive-related behavior, pointing to
a differential role for both hypocretinergic receptors in MD reg-
ulation [31]. Further, Nollet et al. [23] demonstrated that mice
subjected to unpredictable chronic mild stress displayed increased
depressive-like behavior following the tail suspension test and
presented elevated hypocretinergic neuronal activity. These au-
thors were able to reverse this elevation in the hypocretinergic
activity with six weeks of FLX treatment. In human studies, Salo-
mon et al. [29] reported that hypocretin-1 CSF levels were higher
in MD patients, and treatment with sertraline, an SSRI anti-
depressant, resulted in an attenuation of CSF hypocretin-1 levels.
Under our experimental conditions, FLX did not modify hypocre-
tin-1 concentration in the CSF. Interestingly, FLX increased the
prepro-hypocretin mRNA level in the hypothalamus. These results
suggest an eventual increase in the hypocretin synthesis without a
perceptible effect on the release of the peptide toward the ven-
tricular system. However, we cannot discard a local, slower and/or
subtler effect upon hypocretin release that is not expressed in the
CSF concentration. Since the hypocretinergic neurons are involved
in reward and motivation [21], FLX might ameliorate the anhe-
donic component of depression by the modulation of the hypo-
cretinergic function.
It has been suggested that the MCHergic and hypocretinergic
systems reciprocally regulates several physiological functions such
as wakefulness and sleep [16]. It is likely that other functions, like
mood, are also controlled in a reciprocally way by these systems.
In this regards, FLX tended to decrease the MCH/hypocretin-1
concentration ratio (p¼0.057). It is likely that FLX move the bal-
ance between the MCHergic and hypocretinergic neuronal activity,
down-regulating the first in favor of the hypocretinergic side of
the equation.
Finally, it is known that acute treatment with ketamine in-
creases the antidepressant effect of FLX [25]. However, in our ex-
periments, ketamine anesthesia as well as taps and freezing pro-
cedures lasted no more than 20 min, a time that should not be
enough to alter neither the peptides CSF concentrations nor the
gene expression. In addition, this procedure was done both in
control and experimental animals; hence we consider that keta-
mine did not modify the results.5. Conclusions and future directions
The subchronical treatment with FLX decreased the con-
centration of MCH in the CSF. In agreement with the fact that MCH
antagonists have antidepressant effects, the effect of FLX upon the
MCHergic system is a new evidence that support the hypothesis
that MCH is a pro-depressive factor.
New experiments are needed in order to confirm and dissect
the effect of classical antidepressant on the MCHergic and hypo-
cretinergic systems. A new series of experiments in animal models
of depression (chronic mild stress, olfactory bulbectomy, etc.) are
warranted [22]; we hypothesize that the effect of FLX should be
even more pronounced in depressive individuals.Acknowledgements
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